Alnylam reports preliminary fourth-quarter and full-year 2024 product revenues. The company expects to deliver adjusted operating income profitability in 2025.

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced its preliminary* fourth quarter and full year 2024 global net pr...

Alnylam Pharmaceuticals: Commercialization And Early-Stage Studies Are Likely To Drive 2025

Here is how Alnylam Pharmaceuticals (ALNY) and argenex SE (ARGX) have performed compared to their sector so far this year.

Here, we present four biotech stocks, namely SRPT, ADMA, EXEL and ALNY, which most Wall Street analysts are optimistic about. These companies have upside potential for 2025, backed by strong fundament...

Alnylam (ALNY) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the Piper San...

ALNY reports submitting an sNDA in the United States, seeking the label expansion of Amvuttra to treat ATTR amyloidosis with cardiomyopathy.

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that the U.S. Food and Drug Administration (FDA) has accepted fo...

Alnylam shares interim phase I amyloidosis study data on nucresiran, showing rapid TTR reduction sustained for six months after a single dose.

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced the presentation of new results from its Phase 1 study of nucres...

Wolfe Research downgraded Alnylam to Underperform from Peer Perform, citing "unfriendly channel dynamics coupled with inability to rebate."

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present company overviews at the following ...

ALNY's Q3 loss per share matches the Zacks Consensus Estimate and revenues miss the same due to lower collaboration revenues. The stock falls 5.3%.

Alnylam Pharmaceuticals, Inc. (ALNY) Q3 2024 Earnings Call Transcript

While the top- and bottom-line numbers for Alnylam (ALNY) give a sense of how the business performed in the quarter ended September 2024, it could be worth looking at how some of its key metrics compa...

Alnylam Pharmaceuticals (ALNY) came out with a quarterly loss of $0.50 per share in line with the Zacks Consensus Estimate. This compares to earnings of $1.15 per share a year ago.

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today reported its consolidated financial results for the third quarter ended Se...

Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Alnylam (ALNY), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the qu...

Alnylam Pharmaceuticals is a leader in RNAi therapeutics, with multiple FDA-approved treatments and a robust pipeline targeting rare and severe conditions. The company has strong growth potential, par...